NASDAQ OMX

WaferGen Bio-systems Announces ICELL8™ Single-Cell System Placements at the European Molecular Biology Laboratory and Karolinska Institutet

Del

FREMONT, Calif. and LUXEMBOURG, 2016-05-03 23:29 CEST (GLOBE NEWSWIRE) --

WaferGen Bio-systems (NASDAQ:WGBS) announced today that the European Molecular Biology Laboratory (EMBL), an intergovernmental organization specializing in basic research in the life sciences, and Karolinska Institutet, Sweden’s single largest center of medical academic research, have selected the ICELL8™ Single-Cell System for use in their institutions. The system will be used for driving innovative single-cell research in the areas of stem cell and neuroscience research.

“The ability to assess thousands of single cells and select cells of interest with high confidence will provide us with greater understanding of stem cell development and differentiation,” said Dr. Christophe Lancrin, Group Leader at EMBL-Monterotondo.

“We have successfully evaluated the system’s performance to ensure it meets our stringent demands,” said Sten Linnarsson, Professor at Karolinska Institutet. “The system will enable us to accelerate our efforts in identifying and understanding the multiple cell types of the nervous system.”

“The ICELL8 Single-Cell System placements at these leading European research centers are indicative of the growing demand we are seeing for this technology throughout the U.S. and Europe from leading researchers in the field,” said Rollie Carlson, President and CEO WaferGen Biosystems. “These placements represent our initial commercial foray into Europe with the ICELL8 and enhance our position in this large target market.”

The ICELL8 Single-Cell System is a revolutionary platform with the ability to isolate thousands of single cells and process specific cells of interest for downstream analysis using Next Generation Sequencing. The system includes an imaging station and CellSelect™ software for imaging and automatic selection of single cells for downstream processing. The system’s advanced single cell identification and selection provides greater confidence in single-cell analysis results.

About WaferGen
WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research.  The ICELL8™ Single-Cell System is a cutting edge platform which can isolate thousands of single cells and processes specific cells for analysis, including Next Generation Sequencing ("NGS"). The system has demonstrated unbiased isolation of up to 1,800 single cells ranging from 5-100 µm in size on a single chip, including single cells from solid tumors, brain cells, pulmonary airway cells, and multiple cell lines.  The SmartChip™ platform can be used for profiling and validating molecular biomarkers, and can perform massively parallel singleplex PCR for one-step target enrichment and library preparation for clinical NGS.  The Apollo 324™ system can be used to process DNA and RNA from clinical samples to NGS-ready libraries.  These technologies offer a powerful set of tools for biological analysis at the molecular and single cell level in the life sciences, pharmaceutical, and clinical laboratory industries.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the “safe harbor” created by those sections.  Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms.  Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage, our expectations regarding our development of future products including single cell analysis technologies and our expectations concerning our competitive position and business strategy.  Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q.  We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.  We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.  Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

         INVESTOR CONTACTS:
         LifeSci Advisors, LLC
         Brian Ritchie
         BRitchie@LifeSciAdvisors.com
         
         WaferGen Bio-systems, Inc.
         Rollie Carlson
         Rollie.Carlson@wafergen.com

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Aviva Leverages Appian to Deliver on Digital Transformation Initiatives24.10.2017 13:00Pressemelding

With the Appian Platform, Aviva is Anchoring Around the Customer, Removing Complexities and Streamlining Operations RESTON, Va., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announced Aviva, the UK's largest insurer and one of Europe's leading providers of life and general insurance, has deployed Appian's low-code platform to execute on its global digital transformation journey. Putting the customer first helps with Aviva's aim to deliver an unparalleled customer experience. Embedded in three key business units, Appian is helping to transform the way Aviva manages 'Life and Pensions,' 'General Insurance,' and 'Accident and Health.' Aviva has created more than 10 enterprise-grade applications on the Appian platform with a focus on automating processes, streamlining back office operations and creating a single customer view - decreasing operating costs as a result. The company has also digitized pension operations, modernized new produc

eGain Virtual Assistant(TM) named KMWorld Trend-Setting Product for second year in a row24.10.2017 12:30Pressemelding

Solution recognized for delivering a connected, conversational experience SUNNYVALE, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of customer engagement solutions, today announced that its AI-powered solution, eGain Virtual Assistant(TM), has been named in KMWorld Magazine's list of Trend-Setting Products of 2017. Sandra Haimila, Editor at KMWorld, said, "Each year KMWorld looks for software products that break new territory in helping organizations leverage knowledge to achieve their business goals. These products are designed, developed and perfectly timed to fill a niche in the marketplace often before users are even aware that they need such tools." eGain Virtual Assistant is a trend-setter especially because of its integration with human-assisted touchpoints, according to Haimila. Solution highlights: Assists with broad range of inquiries - informational, transactional, and advisory

Dahua Technology H.265 Wi-Fi Cameras A26/C26 Serves Consumer Market24.10.2017 12:26Pressemelding

HANGZHOU, China, Oct. 24, 2017 (GLOBE NEWSWIRE) -- To better serve consumer users, Dahua Technology, a leading solution provider in the global video surveillance industry, released its H.265 Consumer Series products earlier this year. It is now available to most of its markets globally. Below are the details about 2 selected cameras - the indoor cube model C26 and the Pan& Tilt model A26. In an era when people are less and less at home, they are in urgent need of a way to stay connected to it. A26/C26 came along to solve the problem. C26 supports intelligent Human Detection and instant alert, keeping consumers aware of what is going on at home any time they want. Smart Tracking of A26/A46 automatically tracks and keeps tracking any moving object around the camera. Feature Highlights: Fluent High-resolution Video based upon H.265 With 2MP image sensor, A26/C26 delivers crystal clear image. The late

Corporate R&D spending hits record highs for the Top 1000, despite concerns of economic protectionism24.10.2017 08:00Pressemelding

Annual worldwide R&D spending breaks through $700bn for the top 1000 corporate R&D spenders for first time 25% of executives surveyed reported having already experienced some pressure to change how or where they conduct innovation Amazon is the world's largest corporate spender on R&D at over $16bn Alphabet surpasses Apple, according to a global survey of R&D executives, as the Most Innovative Company and for the first time a Chinese company, Alibaba joins the Top 10 Most Innovative Companies list NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Annual worldwide corporate R&D spending broke through $700bn in annual investment, according to an annual analysis of R&D spending across 1000 global public companies by P

TEAM Industries Announces New Innovative Transmission Incorporating Fallbrook's NuVinci® CVP Technology24.10.2017 02:25Pressemelding

Design is ready for vehicle implementation in powered recreational and utility vehicles CEDAR PARK, TEXAS and BAGLEY, MINNESOTA, Oct. 23, 2017 (GLOBE NEWSWIRE) -- TEAM Industries (TEAM) and Fallbrook Technologies Inc. (Fallbrook) announced today that TEAM has a production-ready innovative new transmission design for all-terrain vehicles (ATV) and utility task vehicles (UTV) available to OEMs for vehicle implementation. The transmission incorporates Fallbrook's NuVinci® continuously variable planetary (CVP) technology. NuVinci is a platform technology for a new class of continuously variable transmissions (CVT). It utilizes spheres instead of gears or belts, and can be deployed in a wide variety of applications to improve performance and/or system efficiency. TEAM has an exclusive licensing agreement with Fallbrook for the use of NuVinci CVP technology in North America and Europe in electric and gasoline light vehicle applications. TEAM is also workin

Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging24.10.2017 01:00Pressemelding

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), is pleased to announce that it has entered into a development and commercialization partnership with Advanced Nuclear Medicine Ingredients SA (ANMI). Under the terms of the agreement, Telix and ANMI will partner to commercialise ANMI's 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit (Kit), a proven technology used to accurately image and stage metastatic prostate cancer, in the US market. Telix will also offer the Kit on a worldwide basis as a companion diagnostic imaging agent to the Company's prostate cancer therapeutic (TLX-591)1. The agreement includes filing a Drug Master File (DMF) for the Kit, and completion of the necessary clinical trials to obtain marketing authorisatio

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom